Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 4/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 6/20 | 0.35 |
| ▸ | CA2 | P00918 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13025173 | 0.88 | SIRT5 (0.41) | SIRT5SIRT1SIRT6FOLH1ALB | |
| SCHEMBL13499241 | 0.84 | SIRT5 (0.43) | SIRT5SIRT1SIRT6FOLH1ALB | |
| SCHEMBL4761500 | 0.83 | SIRT6 (0.48) | SIRT5SIRT1SIRT6FOLH1ALB | |
| SCHEMBL12721098 | 0.76 | SIRT6 (0.46) | SIRT5SIRT1SIRT6FOLH1ALB | |
| SCHEMBL12721099 | 0.74 | SIRT5 (0.39) | SIRT5SIRT1SIRT6FOLH1ALB | |
| SCHEMBL10147906 | 0.72 | HIF1A (0.42) | ALDH1A1HPGDKDM4EMAPK1HIF1A | |
| SCHEMBL10167189 | 0.70 | AKT1 (0.37) | SIRT1 | |
| SCHEMBL13021070 | 0.70 | RRM1 (0.39) | SIRT5FOLH1ALBMEN1KMT2A | |
| SCHEMBL14942518 | 0.70 | FOLH1 (0.64) | SIRT5SIRT1SIRT6FOLH1ALB | |
| SCHEMBL25550095 | 0.70 | FOLH1 (0.64) | SIRT5SIRT1SIRT6FOLH1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021761-A1 | Segmented Polymers and Their Conjugates | NEKTAR THERAPEUTICS (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021761-A1 | Segmented Polymers and Their Conjugates | EPCAM, CD44, ECPAS | SIRT5 4359/4885SIRT1 4051/4885SIRT6 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.